Atlas Trials

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Clinical trial NCT05283837 · COMPLETED

Trial details

NCT number
NCT05283837
Sponsor
Zydus Lifesciences Limited
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2022-09-26
Primary completion
2023-09-06
Enrollment
268

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.